TOPLINE: Cancer drugs with higher clinical benefit in pivotal trials and without major safety concerns achieve full US Food and Drug Administration (FDA) approval more quickly. Drugs demonstrating substantial benefits in confirmatory trials, including overall survival improvements, convert from accelerated to full approval in median 2.15 years vs 3.70 years for those without such benefits. […]
The post Faster Cancer Drug Approvals Tied to Clinical Benefits first appeared on News Health.
Author : News Health
Publish date : 2025-03-26 15:05:00
Copyright for syndicated content belongs to the linked Source.